Increasing calories, decreasing morbidity and mortality: Is improved nutrition the answer to better outcomes in patients with biliary atresia?
Christine Carter-Kent,Kadakkal Radhakrishnan,A. Feldstein
DOI: https://doi.org/10.1002/hep.22043
IF: 17.298
2007-11-01
Hepatology
Abstract:Biliary atresia continues to be the most common cause of cirrhosis and end-stage liver disease in the pediatric population in the United States and many other parts of the world. It is characterized by progressive inflammation and fibrosis of both the extrahepatic and intrahepatic bile ducts, leading to obstruction.1,2 Early surgical intervention improves survival but liver transplantation is still required in most patients, and this condition remains the most common pediatric indication for liver transplantation. What do we know about outcomes of patients with biliary atresia? When biliary atresia is detected early, surgical intervention begins with hepatoportoenterostomy (HPE; the Kasai procedure). Developed in 1959, this procedure has made a major improvement on the outcome of patients with this condition.3 The procedure achieves successful bile drainage in up to 80% of patients. If HPE is performed after 3 months of age, there is a significant decline in the success rate.4 However, even after a successful HPE, 70%-80% of patients will eventually go on to require a liver transplantation.4,5 Significant research efforts have been made to identify reliable predictors for progressive disease and poor outcome, because identification of such markers may not only enhance our ability to target and determine the proper timing of currently available therapies but also may aid the development of novel treatment strategies to halt disease progression. A breakthrough in predicting outcomes for pediatric patients with severe liver disease came in 2002. Using data from the Studies of Pediatric Liver Transplantation (SPLIT) registry, the pediatric end-stage liver disease (PELD) score was formulated to assess the risk of poor outcomes in patients awaiting liver transplantation. Components of the PELD score include growth failure (weight and height less than 2 standard deviations below the mean), chronological age less than one year, serum bilirubin, serum albumin, and international normalized ratio.6 Risk factors and outcomes specific for children with biliary atresia have also been examined. In their 2006 article, the Biliary Atresia Research Consortium (BARC) studied the outcome of 104 patients who underwent HPE at 9 clinical centers across the United States.7 Children were followed for 2 years or until loss of their native liver as a result of transplantation or death. At age 24 months, 52% of the children had a “good” outcome defined by the authors as survival without liver transplantation and with total serum bilirubin level 6.0 mg/dL. Patients with serum bilirubin levels 2 mg/dL at 3 months after HPE demonstrated markedly improved survival in comparison to those with total bilirubin 6 mg/dL. Forty-six percent of the patients had a “poor outcome”, defined as death or liver transplantation before 24 months of age. Presence of biliary atresia splenic malformation (BASM), ascites, and cholangitis were predictors of poor outcome. The impact of nutrition and growth was decided to be analyzed separately. In this issue of HEPATOLOGY, DeRusso and colleagues from the BARC address the effect of growth failure on the outcome of these infants.8 As noted by the authors, several previous studies have attempted to address this important issue. Growth failure is an established component of the PELD score, and a significant predictor of graft failure and death after liver transplantation.9 However, most of these studies have been limited by a single cross-sectional assessment of growth parameters. The authors of the current study followed 100 patients from the time of initial evaluation at the BARC center to age 2 years. Growth measurements were followed using age-adjusted z-scores for weight and length and obtained serially at different times allowing for assessment of the impact of growth velocity on patient outcomes. Although the average weight and length z-scores were similar in the good and poor outcome group (as defined previously) at the time of HPE, differences in growth velocity were apparent by 6 Abbreviations: BARC, Biliary Atresia Research Consortium; BASM, biliary atresia splenic malformation; HPE, hepatoportoenterostomy; PELD, pediatric endstage liver disease. This work was supported by NIH grant (DK076852) and the AGA Research Scholar Award (RSA) to A.E.F. Address reprint requests to: Dr. Ariel E. Feldstein, Department of Pediatric Gastroenterology and Cell Biology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195. E-mail: feldsta@ccf.org; fax: 216-444-2974. Copyright © 2007 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hep.22043 Potential conflict of interest: Nothing to report.